Olmutinib for cell activation

Olmutinib (BI 1482694), is a third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). It inhibits both EGFR activating and T790M resistance mutations, while sparing wild-type EGFR. It has been investigated in Phase II clinical trials in patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), who developed resistance to earlier generations of EGFR tyrosine kinase inhibitor therapy.

N/A

1353550-13-6

486.59

Biochemicals

N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; HM61713; BI1482694

C₂₆H₂₆N₆O₂S 

Pale yellow solid

N/A

No

Yes

≥98% by HPLC

DMSO(>40 mg/ml)

-20°C

gel pack

36 months

Protect from air and light

cell

For cells, cell lines and tissues in culture till half confluency.